Modulation of oxidative stress, Serum lipids and renal dysfunction by benazepril in diabetes mellitus

JK Science

Volumn 12, Issue 1, 2010, Pages 11-14

  Garg, Gobind Rai ^a   Khanna, Naresh ^a   Mehta, Kapil Dev ^a   Arora, Tarun ^a   Sharma, Suman Bala ^a   Sharma, Krishna Kishore ^a   Mehta, Ashish K ^a  

^a UNIVERSITY COLLEGE OF MEDICAL SCIENCES   (India)

Author keywords

Benazepril; Diabetes; Oxidative stress; Renal dysfunction; Serum lipids

Indexed keywords

ALLOXAN; BENAZEPRIL; CHOLESTEROL; CREATININE; GLUTATHIONE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MALONALDEHYDE; SUPEROXIDE DISMUTASE; TRIACYLGLYCEROL; UREA;

ALLOXAN DIABETES MELLITUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG MECHANISM; DYSLIPIDEMIA; ENZYME ACTIVITY; ENZYME INDUCTION; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; KIDNEY MASS; LIPID BLOOD LEVEL; MALE; NONHUMAN; OXIDATIVE STRESS; RABBIT; TRIACYLGLYCEROL BLOOD LEVEL; UREA BLOOD LEVEL; URINARY EXCRETION;

EID: 77950661136     PISSN: 09721177     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Ceriello A, Morocutti A, Mercuri F, et al. Defective intracellular antioxidant enzyme production in type 1 diabetic patients with nephropathy. Diabetes 2000; 49: 2170-77.
2. Keidar S, Brooke JG, Rosenbalt M, et al. Involement of macrophage LDL receptor binding domains in the uptake of oxidized LDL. Arterioscler Thromb 1992; 12: 484-93.
3. Aviram M. The contribution of the macrophage receptor for oxidized LDL to its cellular uptake. Biochem Biophys Res Commun 1991; 179: 359-65.
4. Nishiyama A, Nakagawa T, Kobori H, et al. Strict angiotensin blockade prevents the augmentation of intrarenal angiotensin II and podocyte abnormalities in type 2 diabetic rats with microalbuminuria. J Hypertens 2008; 26: 1849-59.
5. Sanz M, Ganado P, Tejerina T. Two angiotensin AT1 receptor antagonists, irbesartan and losartan, effects in cholesterol-fed rabbits. Eur J Pharmacol 2002; 442: 99-106.
6. Singh V P, Le B, Khode R, Baker KM, Kumar R. Intracellular Angiotensin II Production in Diabetic Rats Is Correlated With Cardiomyocyte Apoptosis, Oxidative Stress, and Cardiac Fibrosis. Diabetes 2008; 57: 3297-306.
7. Adams KF. Angiotensin-converting enzyme inhibitor and vascular remodeling in coronary artery disease. Coron Arter Dis 1998; 9: 675-84.
8. Tikellis C, Bialkowski K, Pete J et al. ACE2 Deficiency Modifies Renoprotection Afforded by ACE Inhibition in Experimental Diabetes. Diabetes 2008; 57: 1018-25.
9. Liu XP, Pang YJ, Zhu WW et al. Benazepril, an angiotensinconverting enzyme inhibitor, alleviates renal injury in spontaneously hypertensive rats by inhibiting advanced glycation end-product-mediated pathways. Clin Exp Pharmacol Physiol 2009; 36: 287-96.
10. Bakris GL, Smith AC, Richardson DJ, et al. Impact of an ACE inhibitor and calcium antagonist on microalbuminuria and lipid subfractions in type 2 diabetes: a randomised, multi-centre pilot study. J Hum Hypertens 2002; 16: 185-91.
11. Schlaifer JD, Mancini GB, O' Neill BJ, et al. Influence of smoking status on ACE inhibition-related improvement in coronary endothelial function. TREND investigations. Cardiovasc Drugs Ther 1999; 287: 19-27.
12. Satoh K. Serum lipid peroxide in cerebrovascular disorders determined by a new colorimetric method. Clinica Acta 1978; 90: 37-43.
13. Marklund S, Marklund G. Involvement of the superoxide anion radical in the autoxidation of pyrogallol and a convenient assay for superoxide dismutase. Eur J Biochem 1974; 47: 469-74.
14. Nandi A, Chatterjee IB. Assay of superoxide dismutase activity in animal tissues. J Biosci 1988; 13: 305-15.
15. Inouye M, Mio T, Sumino K. Link between glycation and lipoxidation in red blood cells in diabetes. Clin Chim Acta 1999; 285: 35-44.
16. Gumieniczek A, Hopkala H, Wójtowicz Z, Nikolajuk J. Changes in antioxidant status of heart muscle tissue in experimental diabetes in rabbits. Acta Biochimica Polonica 2002; 49: 529-35.
17. Hayek T, Attias J, Smith J, Breslow JL, Keidar S. Antiatherosclerotic and antioxidant effects of captopril in apolipoprotein E-deficient mice. J Cardiovasc Pharmacol 1998; 31: 540-44.
18. Hayek T, Keidar S, Mein Y, Oiknin J, Breslow J. Effect of angiotensin converting enzyme inhibitors on LDL lipid peroxidation and atherosclerosis in apo-E deficient mice. Circulation 1995; 92: 2998.
19. Ruggenenti P, Mise N, Pisoni R, et al. Diverse effects of increasing lisinopril doses on lipid abnormalities in chronic nephropathies. Circulation 2003; 107: 586-92.
20. Ono Y, Nakaya Y, Bando S, et al. Telmisartan decreases plasma levels of asymmetrical dimethyl-L-arginine and improves lipid and glucose metabolism and vascular function. Int Heart J 2009; 50: 73-83.
21. Leehey DJ, Singh AK, Alavi N, Singh R. Role of angiotensin II in diabetic nephropathy. Kidney Int Suppl 2000; 77: S93-98.
22. Melchior WR, Bindlish V, Jaber LA. Angiotensin-converting enzyme inhibitors in diabetic nephropathy. Ann Pharmacother 1993; 27: 344-50.
23. Jacobsen P, Andersen S, Jensen BR, Parving HH. Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy. J Am Soc Nephrol 2003; 14: 992-99.